Skip to main content
. Author manuscript; available in PMC: 2022 Feb 10.
Published in final edited form as: J Control Release. 2020 Nov 19;330:284–292. doi: 10.1016/j.jconrel.2020.11.031

Fig. 5. Pre-exposure prophylaxis efficacy of ciprofloxacin drugamer against a clinical isolate of Burkholderia pseudomallei.

Fig. 5.

PBS, free ciprofloxacin (free drug) or drugamer were intratracheally administered (50 μL aerosolization, 20 mg ciprofloxacin/kg) at day −2, −1, and 0 using a MicroSprayer® (n = 10 for each treatment group). PBS was used as a carrier control. All mice were challenged with aerosolized B. pseudomallei 2h after dosing on day 0. Survival rate and health condition of mice were monitored for 14 days. (A) Survival rate of infected mice. Arrows indicate dosing day. (B & C) Body weight and surface temperature of mice over the course of the experiment. (D) Clinical scores of mice. Mice were scored on seven categories: activity, coat, eyes, breathing, posture, isolation, and resistance to handling, with scores of 0, 0.5, and 1 specified for each category. (E) Bacterial burden in organs retrieved from mice that survived to the experimental endpoint (14 days). CFU: Colony-forming unit. Data are presented as mean ± SD.